Deciphera Pharmaceuticals Inc. CEO Steven Hoerter told BioWorld the FDA approval of Turalio (pexidartinib) from Daiichi Sankyo Co. Ltd. last week "leaves a lot of headroom for efficacy," given the response rate of about 40%.